trans-1-(1-adamantyl)-3-(3-pyridyl)-2-propen-1-one | 153872-60-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: trans-1-(1-adamantyl)-3-(3-pyridyl)-2-propen-1-one
• 英文别名: 1-Adamantan-1-yl-3-pyridin-3-yl-propenone；(E)-1-(1-adamantyl)-3-pyridin-3-ylprop-2-en-1-one
• CAS: 153872-60-7
• 化学式: C₁₈H₂₁NO
• 分子量: 267.371
• InChiKey: KGUFQIMIYFOJOF-ONEGZZNKSA-N

物化性质

• 沸点：
  426.0±20.0 °C(predicted)
• 密度：
  1.175±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  trans-1-(1-adamantyl)-3-(3-pyridyl)-2-propen-1-one 在 盐酸羟胺 、 sodium acetate 作用下， 以 甲醇 、 水 为溶剂， 反应 21.0h， 以49%的产率得到(E)-1-Adamantan-1-yl-3-pyridin-3-yl-propenone oxime
  参考文献：
  名称：

  Kozlov, N. G.; Skakovskii, E. D.; Korotyshova, G. P., Russian Journal of General Chemistry, 1997, vol. 67, # 10, p. 1602 - 1605

  摘要：

  DOI：
• 作为产物：
  描述：

  3-吡啶甲醛 、 1-金刚烷甲酮 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 以62%的产率得到trans-1-(1-adamantyl)-3-(3-pyridyl)-2-propen-1-one
  参考文献：
  名称：

  [EN] 1 IBETA- HYDROXYSTEROID DEHYDROGENASE INHIBITORS
  [FR] COMPOSÉ

  摘要：

  公开号：

  WO2009106817A3

文献信息

• Pyridyl-propan-2-yl esters of 1-adamantane carboxylates
  申请人：British Technology Group Limited

  公开号：US05595995A1

  公开（公告）日：1997-01-21

  Compounds having the general formula: ##STR1## wherein each of R.sup.1 and R.sup.2 independently represents hydrogen or alkyl of 1 to 4 carbon atoms; A represents --O-- or --CR.sup.4 R.sup.5, where R.sup.4 and R.sup.5 are defined as for R.sup.1 or R.sup.2 ; R.sup.3 represents an adamantyl group; and Py represents a 3- or 4-pyridyl group, as free bases or their pharmaceutically acceptable salts are useful in treating androgen-dependent, especially prostatic, cancer.

  具有一般式：##STR1##其中R.sup.1和R.sup.2每个独立地表示1至4个碳原子的氢或烷基; A表示--O--或--CR.sup.4 R.sup.5，其中R.sup.4和R.sup.5的定义与R.sup.1或R.sup.2相同; R.sup.3表示一个金刚烷基; Py表示3-或4-吡啶基，作为自由碱或其药学上可接受的盐在治疗雄激素依赖性，尤其是前列腺癌方面是有用的。
• COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE
  申请人：Vicker Nigel

  公开号：US20110112151A1

  公开（公告）日：2011-05-12

  There is provided a compound of formula R 1 —CO—X—Y—Z—R 2 wherein X and Z are each optional groups that are, independently, saturated or unsaturated carbon chains having a length of 1 to 3 carbons; Y is SO, S, SO 2 , CH═CH, CH 2 CH 2 or O; R 1 is wherein denotes the point of attachment; R 2 is a heteroaryl group comprising an optionally substituted 5 or 6 membered ring, which ring contains only carbon and at least one nitrogen, or contains only carbon, and at least two nitrogens and at least one sulfur; and wherein (i) when R 1 is and —CO—X—Y—Z— is CO—CH 2 —SO, CO—CH 2 —S, or CO—CH 2 —SO 2 , R 2 is other than and; (ii) when R 1 is and —CO—X—Y—Z— is —CO—CH 2 —O—, R 2 is other than

  提供了一个化合物的公式R1—CO—X—Y—Z—R2，其中X和Z是可选的基团，它们分别是具有1至3个碳原子的饱和或不饱和碳链；Y是SO、S、SO2、CH═CH、CH2CH2或O；R1是其中的连接点；R2是一个杂环基团，包括一个可选取代的5或6元环，该环仅包含碳和至少一个氮，或仅包含碳、至少两个氮和至少一个硫；其中(i)当R1是且—CO—X—Y—Z—为CO—CH2—SO、CO—CH2—S或CO—CH2—SO2时，R2不是和；(ii)当R1是且—CO—X—Y—Z—为—CO—CH2—O—时，R2不是。
• Synergism of virtual screening and medicinal chemistry: Identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1
  作者：Tobias Noeske、Dina Trifanova、Valerjans Kauss、Steffen Renner、Christopher G. Parsons、Gisbert Schneider、Tanja Weil

  DOI：10.1016/j.bmc.2009.05.072

  日期：2009.8

  We report the identification of novel potent and selective metabotropic glutamate receptor 1 (mGluR1) antagonists by virtual screening and subsequent hit optimization. For ligand-based virtual screening, molecules were represented by a topological pharmacophore descriptor (CATS-2D) and clustered by a self-organizing map (SOM). The most promising compounds were tested in mGluR1 functional and binding assays. We identified a potent chemotype exhibiting selective antagonistic activity at mGluR1 ( functional IC50 = 0.74 +/- 0.29 mu M). Hit optimization yielded lead structure 16 with an affinity of K-i = 0.024 +/- 0.001 mu M and greater than 1000-fold selectivity for mGluR1 versus mGluR5. Homology-based receptor modelling suggests a binding site compatible with previously reported mutation studies. Our study demonstrates the usefulness of ligand-based virtual screening for scaffold-hopping and rapid lead structure identification in early drug discovery projects. (C) 2009 Elsevier Ltd. All rights reserved.
• Synthesis and hepatoprotector activity of aminoketones of the adamantane series
  作者：N. G. Kozlov、G. P. Korotyshova

  DOI：10.1007/bf02510087

  日期：1999.8
• KOZLOV, N. S.;SHMANAJ, G. S.;KOROTYSHOVA, G. P., VESTSI AN BSSR. CEP. XIM. N.,(1991) N, S. 60-65
  作者：KOZLOV, N. S.、SHMANAJ, G. S.、KOROTYSHOVA, G. P.

  DOI：——

  日期：——